Indaptus Therapeutics, Inc. Increase (Decrease) in Other Operating Assets
Indaptus Therapeutics, Inc. (INDP) reported Increase (Decrease) in Other Operating Assets of $1.08 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2025-11-12
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$249.95K.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-06-30 was $571.69K.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-03-31 was $762.34K, a 38.40% decline year-over-year.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2024-12-31 was -$1.15M.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$474.06K, a 169.66% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2023 was $680.52K, a 5.72% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2022 was $721.77K, a 4280.49% increase from fiscal 2021.
- Indaptus Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2021 was $16.48K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$249.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $321.74K derived: sum of 2 quarters · filed 2025-11-12 | $1.08M 10-Q · filed 2025-11-12 | -$63.81K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $571.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.33M 10-Q · filed 2025-08-13 | $186.14K derived: sum of 3 quarters · filed 2025-08-13 | $12.47K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-03-31 | $762.34K 10-Q · filed 2025-05-14 | -$385.55K derived: sum of 2 quarters · filed 2025-05-14 | -$559.22K derived: sum of 3 quarters · filed 2025-11-12 | -$949.22K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$1.32M derived: sum of 2 quarters · filed 2025-11-12 | -$1.71M derived: sum of 3 quarters · filed 2025-11-12 | -$474.06K 10-K · filed 2025-03-13 |
| 2024-09-30 | -$173.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$563.67K derived: sum of 2 quarters · filed 2025-11-12 | $673.83K 10-Q · filed 2025-11-12 | $265.56K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$390.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $847.50K 10-Q · filed 2025-08-13 | $439.24K derived: sum of 3 quarters · filed 2025-08-13 | $177.80K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-14 | $829.23K derived: sum of 2 quarters · filed 2025-05-14 | $567.80K derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$408.26K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$669.70K derived: sum of 2 quarters · filed 2025-03-13 | $680.52K 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$261.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.09M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $1.35M 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | -$16.48K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $79.20K derived: sum of 2 quarters · filed 2024-03-13 | $721.77K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $95.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $738.25K 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $642.57K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $16.48K 10-K · filed 2023-03-17 | |||
| 2021-06-30 | -$40.45K 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | -$2.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |